High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis

• Published in: Frontiers in immunology Vol. 14; p. 1161832
• Main Authors: De Luca, Geraldine, Lev, Paola R, Camacho, Maria F, Goette, Nora P, Sackmann, Federico, Castro Ríos, Miguel A, Moiraghi, Beatriz, Cortes Guerrieri, Veronica, Bendek, Georgina, Carricondo, Emiliano, Enrico, Alicia, Vallejo, Veronica, Varela, Ana, Khoury, Marina, Gutierrez, Marina, Larripa, Irene B, Marta, Rosana F, Glembotsky, Ana C, Heller, Paula G
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 16-11-2023
• Subjects: AIM2 inflammasome; cell-free DNA; Cell-Free Nucleic Acids; Cytokines - metabolism; Disease Progression; DNA; Humans; IL-18; Immunology; Inflammasomes - metabolism; inflammation; Inflammation - chemically induced; Interleukin-18 - metabolism; myelofibrosis; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; NLRP3 inflammasome; Primary Myelofibrosis - genetics; monocytes; myelofibrosis; inflammation; AIM2 inflammasome; IL-18; cell-free DNA; JAK2; NLRP3 inflammasome
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1161832

Myelofibrosis (MF) is a clonal hematopoietic stem cell disorder classified among chronic myeloproliferative neoplasms, characterized by exacerbated myeloid and megakaryocytic proliferation and bone marrow fibrosis. It is induced by driver (
/
/
) and high molecular risk mutations coupled to a sustained inflammatory state that contributes to disease pathogenesis. Patient outcome is determined by stratification into risk groups and refinement of current prognostic systems may help individualize treatment decisions. Circulating cell-free (cf)DNA comprises short fragments of double-stranded DNA, which promotes inflammation by stimulating several pathways, including inflammasome activation, which is responsible for IL-1β and IL-18 maturation and release. In this work, we assessed the contribution of cfDNA as a marker of disease progression and mediator of inflammation in MF. cfDNA was increased in MF patients and higher levels were associated with adverse clinical outcome, a high-risk molecular profile, advanced disease stages and inferior overall survival, indicating its potential value as a prognostic marker. Cell-free DNA levels correlated with tumor burden parameters and markers of systemic inflammation. To mimic the effects of cfDNA, monocytes were stimulated with poly(dA:dT), a synthetic double-stranded DNA. Following stimulation, patient monocytes released higher amounts of inflammasome-processed cytokine, IL-18 to the culture supernatant, reflecting enhanced inflammasome function. Despite overexpression of cytosolic DNA inflammasome sensor AIM2, IL-18 release from MF monocytes was shown to rely mainly on the NLRP3 inflammasome, as it was prevented by NLRP3-specific inhibitor MCC950. Circulating IL-18 levels were increased in MF plasma, reflecting
inflammasome activation, and highlighting the previously unrecognized involvement of this cytokine in MF cytokine network. Monocyte counts were higher in patients and showed a trend towards correlation with IL-18 levels, suggesting monocytes represent a source of circulating IL-18. The close correlation shown between IL-18 and cfDNA levels, together with the finding of enhanced DNA-triggered IL-18 release from monocytes, suggest that cfDNA promotes inflammation, at least in part, through inflammasome activation. This work highlights cfDNA, the inflammasome and IL-18 as additional players in the complex inflammatory circuit that fosters MF progression, potentially providing new therapeutic targets.